Galcanezumab + Placebo

Phase 2Completed

1 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Migraine Headache

Conditions

Migraine Headache

Trial Timeline

Jul 7, 2014 → Feb 12, 2018

NCT ID

NCT02163993

About Galcanezumab + Placebo

Galcanezumab + Placebo is a phase 2 stage product being developed by Eli Lilly for Migraine Headache. The current trial status is completed. This product is registered under clinical trial identifier NCT02163993. Target conditions include Migraine Headache.

What happened to similar drugs?

20 of 20 similar drugs in Migraine Headache were approved

Approved (20) Terminated (1) Active (0)

✅Galcanezumab + ErenumabEli LillyApproved

✅Galcanezumab + Rimegepant + Placebo + PlaceboEli LillyApproved

✅Emgality 120 MG in 1 ML Prefilled SyringeEli LillyApproved

✅tramadol HCl/acetaminophenJohnson & JohnsonApproved

✅topiramate; almotriptan malateJohnson & JohnsonApproved

✅Ubrogepant 50 MG [Ubrelvy] + Ubrogepant 100 MG [Ubrelvy]AbbVieApproved

✅Atogepant 60 mg + Propranolol 160 mg + Topiramate 100 mgAbbVieApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (12)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04616326	Phase 3	Active	Nov 25, 2020	Mar 1, 2027	Chronic Migraine
NCT04085289	Phase 1	Completed	Nov 20, 2019	May 21, 2020	Healthy
NCT03963232	Phase 3	Completed	Jul 30, 2019	Mar 11, 2022	Episodic Migraine
NCT03559257	Phase 3	Completed	Jul 31, 2018	Sep 19, 2019	Migraine
NCT03432286	Phase 3	Active	Mar 14, 2018	Nov 1, 2026	Episodic Migraine
NCT02959177	Phase 2	Completed	Nov 9, 2016	Jan 18, 2019	Migraine
NCT02614196	Phase 3	Completed	Dec 4, 2015	Oct 5, 2018	Migraine
NCT02614261	Phase 3	Completed	Nov 30, 2015	Jul 14, 2021	Chronic Migraine
NCT02614183	Phase 3	Completed	Nov 30, 2015	Aug 9, 2018	Migraine
NCT02576951	Phase 1	Completed	Oct 19, 2015	Jan 8, 2018	Healthy
NCT02397473	Phase 3	Completed	May 22, 2015	Jun 4, 2018	Episodic Cluster Headache
NCT02163993	Phase 2	Completed	Jul 7, 2014	Feb 12, 2018	Migraine Headache

Competing Products

20 competing products in Migraine Headache

See all competitors

Product	Company	Stage	Hype Score
DFN-11	Dr. Reddy's Laboratories	Phase 2	32
DFN-15 Active	Dr. Reddy's Laboratories	Phase 3	37
DFN-15 (fasted) + DFN-15 (fed) + Comparator Celebrex® (fed)	Dr. Reddy's Laboratories	Phase 1	26
DFN-11	Dr. Reddy's Laboratories	Phase 3	37
DFN-02	Dr. Reddy's Laboratories	Phase 3	37
DFN-15 Dose A (treatment A) + DFN-15 Dose B (treatment B)	Dr. Reddy's Laboratories	Phase 2	32
DFN-15	Dr. Reddy's Laboratories	Phase 2	32
ABP-450	AEON Biopharma	Phase 2	17
Lasmiditan + Placebo	Eli Lilly	Phase 3	40
Placebo + LY2300559	Eli Lilly	Phase 2	27
lasmiditan 200 mg + Sumatriptan + matching placebo	Eli Lilly	Phase 1	29
ABP-450 + Placebo	AEON Biopharma	Phase 2	25
Lasmiditan + Placebo	Eli Lilly	Phase 2	35
Ketorolac + Prochlorperazine + Diphenhydramine	Assertio Holdings	Phase 2	17
Galcanezumab + Erenumab	Eli Lilly	Approved	43
Aricept (donepezil hydrochloride)	Eisai	Phase 2	35
E2007	Eisai	Phase 2	35
Galcanezumab + Rimegepant + Placebo + Placebo	Eli Lilly	Approved	43
Galcanezumab + Placebo	Eli Lilly	Phase 3	40
Lasmiditan + Placebo	Eli Lilly	Phase 2	35